Metabolic associated fatty liver disease (MAFLD) has become the most common chronic liver disease in the world, and its incidence is increasing year by year. At present, there is no specific drug. Based on the theory of "gut-liver axis", this paper briefly describes the treatment of MAFLD with traditional Chinese medicine colon dialysis, in order to provide new ideas and references for clinical treatment of MAFLD.

Yuanjing Xie, Jianmei Hao. Treatment of Metabolic Associated Fatty Liver Disease with Traditional Chinese Medicine Colon Dialysis Based on "Gut-liver Axis". Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 9: 57-62. https://doi.org/10.25236/AJMHS.2023.040909.

[1] Boeckmans J, Rombaut M, Demuyser T, et al. Infections at the nexus of metabolic-associated fatty liver disease[J]. Arch Toxicol, 2021, 95(7):2235-2253. 

[2] Sakurai Y, Kubota N, Yamauchi T, et al. Role of Insulin Resistance in MAFLD [J]. Int J Mol Sci, 2021, 22(8):4156

[3] Eslam M, Sanyal AJ, George J, et al. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7):1999-2014. 

[4] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. [J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851-861.

[5] Shepard CR. TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism[J]. Front Endocrinol (Lausanne), 2021, 11:613639. 

[6] Mandato C, Delli Bovi AP, Vajro P. The gut-liver axis as a target of liver disease management. Hepatobiliary Surg Nutr. 2021 Jan;10(1):100-102. 

[7] Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in nonalcoholic fatty liver disease[ J]. Children (Basel), 2017, 4(8): 66. 

[8] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome [J]. Nat Rev Gastroenterol Hepatol. 2018, 15(7):397-411.

[9] Wahlström A, Sayin SI, Marschall HU, Bäckhed F, et al. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolis[J]. Cell Metab, 2016, 24(1): 41-50.

[10] Schneider KM, Albers S, Trautwein C. Role of bile acids in the gut-liver axis [J]. J Hepatol, 2018, 68(5): 1083-1085.

[11] Hild B, Heinzow HS, Schmidt HH, et al. Bile Acids in Control of the Gut-Liver-Axis[J]. Z Gastroenterol, 2021, 59(1): 63-68.

[12] Shao T, Zhao C, Li F, et al. Intestinal HIF-1alpha deletion exac-erbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction [J] .J Hepatol, 2018, 69(4): 886-895. 

[13] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy [J]. J Hepatol, 2020, 72(3):558-577. 

[14] Wang R, Tang R, Li B, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cell Mol Immunol, 2021, 18(1): 4-17.

[15] Tito RY, Chaffron S, Caenepeel C, et al. Population-level analysis of Blastocystis subtype prevalence and variation in the human gut mi-crobiota[J]. Gut, 2019, 68(7):1180-1189. 

[16] Chen Yingjie, Analysis on the communication between liver and large intestine[J]. Traditional Chinese Medicinal Research, 2007, 20(11):3-8. 

[17] Zhang Wei, Li Huanan, The research idea of abdominal massage therapy for nonalcoholic fatty liver disease based on enteric-liver axis, Zhao Na, et al. [J]. Liaoning Journal of Traditional Chinese Medicine, 2017, 44(9): 1857-1859. 

[18] Wang Min, Zhou Lu, Sun Yan, et al. Relevant Analysis of Dachaihu Decoction and its“Formula Elements”on the“Intesine-liver axis”in the NAFLD Model[J]. World Chinese Medicine, 2021, 16(3): 430-436. 

[19] Gao Wenyuan, Yu Jiayong, Hua Jun, et al. Clinical study on the treatment of nonalcoholic fatty liver with self-made Yiqi Shugan Jianpi decoction[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2021, 31(3): 209-212. 

[20] Wu Di, Xie Chun’e, Li Feng, et al. Effect of Yinchen Linggui prescription on intestinal mucosal barrier in rats with non-alcoholic fatty liver disease based on gut-liver axis[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2021, 30(6): 571-577. 

[21] Zhang Jianlin, Wang Yan, Huang Yuanhang, et al. Curative effect of rhubarb plus sequential colon dialysis on early and middle stage chronic renal failure The Journal of Practical Medicine[J]. The Journal of Practical Medicine, 2005(09):985-986. 

[22] Wei Jinhua, Zhang Cuiqin, Zhang Shujuan, et al. Clinical observation of 32 patients with early and middle stage chronic renal failure treated by colon dialysis[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2014, 15(03):228-229. 

[23] Guo Jianchun, Shi Junping, Chen Qunwei, et al. The Study on the Effects of Colon Herbal Dialysis in Patients with Chronic Severe Hepatitis B[J]. Chinese Archives of Traditional Chinese Medicine, 2006(07):1254-1256. 

[24] Liang Xuelin, Wang Zhiyu, Li Xiaolin, et al. Clinical Effect of Colon Herbs Dialysis Therapy in Treating Non-alcoholic Fatty Liver Disease[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 2008(06):340-341. 

[25] Zhang Xiaoxing, Liu Yandong, Yang Chuan, Clinical Study of Baogan Jiedu Decoction Retention Enema Combined with Silybin in the Treatment of Nonalcoholic Steatohepatitis[J]. Acta Chinese Medicine and Pharmacology, 2020, 48(10):47-51. 

[26] Yuan Chao, Kong Ying, Li Shufang, et al. Therapeutic effect of colon approach therapy combined with traditional Chinese medicine retention enema on 40 cases of nonalcoholic fatty liver[J]. Modern Traditional Chinese Medicine, 2017, 37(01):11-13. 

[27] Barchetta I, Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. [J]. Nutrients, 2020, 12(11):3302.